Shah R, et al. - In 5–10% of patients with coronary stents, oral anticoagulation (OAC) is indicated along with dual antiplatelet therapy (DAPT), so researchers sought the ideal length of this triple antithrombotic therapy (TAT). Analyzing data from three randomized clinical trials and 1,883 patients, they observed lower rates of major adverse cardiovascular events, cardiac mortality, all-cause mortality, and any-bleeding events with short-term TAT vs long-term TAT, but comparable rates of myocardial infarction, stroke, stent thrombosis, and thrombolysis in myocardial infarction major bleeding between the two groups. Reduced rates of major adverse cardiovascular events, cardiac mortality, all-cause mortality, and any-bleeding was seen with short-term TAT vs 12-month TAT, but rates were comparable to 6-month TAT. These findings suggest better effectiveness and safety outcomes are related to short-term TAT vs long-term TAT among patients who require chronic OAC therapy and undergo coronary stent placement.